Becton Dickinson: Vegas Takes

Research evidence excerpt

Becton Dickinson: Vegas Takes

Accessible version

Becton Dickinson

Vegas Takes

Maintain Rating: NEUTRAL | PO: 177.00 USD | Price: 147.51 USD

Fireside chat with CEO Tom Polen and CFO Vitor Roque 12 May 2026

We hosted BDX CEO Tom Polen and Vitor Roque at our Healthcare conference in Vegas. Equity

We discussed key topics including Vitor as CFO, new BD portfolio and growth outlook,

Travis Steed

recent headwinds on the business, and macro outlook. Research Analyst

BofAS

Vitor focused on consistent, transparent guidance travis.steed@bofa.com

Stephanie Elghazi

Vitor Roque is coming in as CFO at a pivotal time for BDX as the Life Sciences Research Analyst

transaction just closed. As CFO, Vitor wants to make sure that BDX is consistent and BofAS stephanie.elghazi@bofa.com

transparent in its guidance. Vitor has more than 20 years of experience at BDX across

Enjia Cao

geographies and businesses (biosciences, medication management) and has the Research Analyst

operational rigor to drive the New BD strategy. Vitor will partner with Tom and the BofAS enjia.cao@bofa.com

leadership team to unlock growth. Another priority will be capital allocation, with a focus

Gracia Mahoney

on share buybacks, maximizing shareholder return, continued investment in the business, Research Analyst

tucks in acquisitions, and delevering the balance sheet. Vitor was an integral part of BofASgracia.mahoney@bofa.com

building the guidance for this year. Aidan Lahey

Research Analyst

More clarity in New BD structure BofASaidan.lahey@bofa.com

BDX has spent the last 5 yrs being very active in reshaping the portfolio (exited diabetes, Rei Tan

V Mueller, and Life Sciences). 10 years ago the medtech business was $4.5bn (60% of Research Analyst

BD) and today it is $19bn while Life Sciences stayed around $3bn.